Kato, Masaki
Yokoyama, Chihiro
Kawasaki, Akihiro
Takeda, Chiho
Koike, Taku
Onoe, Hirotaka
Iriki, Atsushi
Funding for this research was provided by:
Japan Society for the Promotion of Science (KAKENHI 23700317, KAKENHI 25330180, KAKENHI 25293254, KAKENHI 26118517, KAKENHI 16H01493)
Japan Agency for Medical Research and Development (Brain Mapping by Integrated Neurotechnologies for Disease Studies)
Article History
Received: 3 July 2017
Revised: 12 February 2018
Accepted: 15 February 2018
First Online: 27 February 2018
Compliance with ethical standards
:
: AI is the president and CEO of RIKAENALYSIS Corporation (RIKEN Venture, Tokyo). The other authors declare no competing financial interests.
: All experimental procedures and handling methods were performed in accordance with the Guidelines for Conducting Animal Experiments of RIKEN, where the experiments were conducted, and the recommendations of the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (ExternalRef removed). All procedures were approved by the Animal Care and Use Committee of the Kobe Institute of RIKEN (MAH21-10-8) and the Brain Science Institute of RIKEN [H22-2-216(4), H24-2-228(5)].